What is the difference between Exenatide and Semaglutide?

Exenatide: First GLP-1 receptor agonist approved for clinical use (2005), derived from the Gila monster venom peptide exendin-4. Available as twice-daily immediate-release (Byetta) and once-weekly extended-release (Bydureon BCise) formulations. Established the GLP-1 agonist drug class and provided the foundational clinical evidence for cardiovascular and metabolic benefits. Semaglutide: Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management. It is FDA-approved under the brand names Ozempic (diabetes) and Wegovy (weight loss) and has become one of the most widely discussed peptides in mainstream health conversations. Both are in the GLP-1 & Metabolic category but differ in mechanism, dosing, and research evidence — see the full comparison.

Can you take Exenatide and Semaglutide together?

There is no specific, well-documented interaction rule for combining Exenatide and Semaglutide in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, Exenatide or Semaglutide?

Exenatide is currently fda-approved and Semaglutide is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

GLP-1 & Metabolic · Comparison

Exenatide vs Semaglutide

A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

Exenatide

FDA-approved

First GLP-1 receptor agonist approved for clinical use (2005), derived from the Gila monster venom peptide exendin-4. Available as twice-daily immediate-release (Byetta) and once-weekly extended-release (Bydureon BCise) formulations. Established the GLP-1 agonist drug class and provided the foundational clinical evidence for cardiovascular and metabolic benefits.

Full profile

Semaglutide

FDA-approved

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management. It is FDA-approved under the brand names Ozempic (diabetes) and Wegovy (weight loss) and has become one of the most widely discussed peptides in mainstream health conversations.

Full profile

	Exenatide	Semaglutide
Category	GLP-1 & Metabolic	GLP-1 & Metabolic
Also known as	Byetta, Bydureon, AC2993, exendin-4	Ozempic, Wegovy, Rybelsus, GLP-1 agonist
Evidence	FDA-approved	FDA-approved
Dosing range	5mcg–2mg (weekly ER) mcg, Twice daily (immediate-release) or once weekly (extended-release)	0.25mg–2.4mg mg, once weekly (injectable); once daily (oral Rybelsus)
Administration	Subcutaneous injection	Subcutaneous injection (weekly — Ozempic/Wegovy), Oral tablet (daily — Rybelsus)
Key side effects	Nausea (most common, especially initial weeks), Vomiting, Diarrhea, Injection site nodules (extended-release formulation)	Nausea (very common, especially during dose escalation), Vomiting, Diarrhea or constipation, Reduced appetite (intended effect)
Cited sources	2 references	4 references

Key differences

Administration: Exenatide — Subcutaneous injection; Semaglutide — Subcutaneous injection (weekly — Ozempic/Wegovy), Oral tablet (daily — Rybelsus).
Dosing units differ: Exenatide is dosed in mcg, Semaglutide in mg — they operate at different scales.
Frequency: Exenatide is typically Twice daily (immediate-release) or once weekly (extended-release); Semaglutide is once weekly (injectable); once daily (oral Rybelsus).
Research depth: this profile cites 2 sources for Exenatide vs 4 for Semaglutide.

How each works

Exenatide

Exenatide was identified from Gila monster (Heloderma suspectum) venom as exendin-4, a peptide with ~53% homology to human GLP-1 but with DPP-4 resistance enabling longer activity. Clinical trials demonstrated HbA1c reductions of 0.8–1.0%, weight loss of 2–4kg, and cardiovascular safety (EXSCEL trial showed non-inferiority). The extended-release microsphere formulation achieved comparable efficacy with once-weekly dosing.

Semaglutide

Semaglutide has robust clinical trial data — including the STEP and SUSTAIN trial series — demonstrating significant weight loss (15–20% body weight), glycemic control, and cardiovascular risk reduction. It works by mimicking the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, and reducing appetite via central nervous system signaling.

Read the full Exenatide profile Read the full Semaglutide profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.